Aftercare for patients with transplanted organs;Nachsorge bei organtransplantierten

Deutsches Arzteblatt

Volumn 106, Issue 9, 2009, Pages 148-156

  Schrem, Harald ^a   Barg Hock, Hannelore ^a   Strassburg, Christian P ^a   Schwarz, Anke ^a   Klempnauer, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cooperation; Organ transplantation; Quality of life; Rehabilitation; Treatment outcome

Indexed keywords

AMPHOTERICIN B; BEZAFIBRATE; COTRIMOXAZOLE; CYCLOSPORIN A; IBANDRONIC ACID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; PAMIDRONIC ACID; PREDNISOLONE; PROTON PUMP INHIBITOR; RAPAMYCIN; SULFONYLUREA; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VITAMIN D;

BONE MARROW SUPPRESSION; CANCER SCREENING; DIABETOGENESIS; DIARRHEA; GRAFT RECIPIENT; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN TREATMENT; KIDNEY FAILURE; LIVER TOXICITY; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PATIENT CARE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

AFTERCARE; GERMANY; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 63449127200     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0148     Document Type: Review

References (24)

1. Schrem H, Till N, Becker T et al.: Langzeit-Outcome nach Leber- transplantation. Chirurg 2008; 79(2): 121-9.
2. Taylor AL, Watson CJ, Bradley JA: Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56(1): 23-46.
3. Schlitt HJ, Barkmann A, Böker KH: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001: 357: 587-91.
4. Schrem H, Luck R, Becker T, Nashan B, Klempnauer J: Update on liver transplantation using cyclosporine. Transplant Proc 2004; 36: 2525-31.
5. Kobashigawa JA: Statins in solid organ transplantation: Is there an immunsosuppressive effect? Am J Transplant 2004; 4:1013-8.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
7. Wilkinson A, Davidson J, Dotta F et al.: Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291-8.
8. Mayr M: Management nach Transplantation. Ther Umschau 2005; 62: 487-501.
9. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH: New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007; 36: 873-90.
10. EBPG Expert Group on Renal Transplantation: European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant 2002; 4:25-6.
11. Mells G, Neuberger J: Reducing the risks of cardiovascular disease in liver allograft recipients.Transplantation 2007; 83:1141-50.
12. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-53.
13. Chobanian AV, Bakris GL, Black HR, et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-72.
14. Ojo AO: Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007; 27: 498-507.
15. Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-91.
16. Birkeland SA, Hamilton-Dutoit S: Is postttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76:984-8.
17. Traywick C, O'Reilly FM: Management of skin cancer in solid organ transplant recipients. Dermatol Ther 2005; 18: 12-8.
18. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582-8.
19. Torres A, Lorenzo V, Salido E: Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13:551-8.
20. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis 2003; 42:S1-201.
21. Kanis JA, Johansson H, Oden A, et al.:A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893-9.
22. Cruz DN, Brickel HM, Wysolmerski JJ, et al.:Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant 2002; 2:62-7.
23. Abbott KC, Oglesby RJ, Agodoa LY: Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int. 2002; 62: 2250-6.
24. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14.